Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Sodium-Glucose cotransporter-2 inhibitors
3 evidence topics · 4 sources
SGLT2 inhibitor recommendations: KDIGO 2024 CKD guideline
Dapagliflozin in biopsy-confirmed FSGS: DAPA-CKD prespecified analysis
“Of 104 participants with biopsy-confirmed FSGS, 45 were randomized to dapagliflozin and 59 to placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The primary outcome occurred in 4 (8.9%) and 7 (11.9%) participants randomized to dapagliflozin and placebo, respectively [hazard ratio 0.62, 95% confidence interval (95% CI) 0.17, 2.17].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Thereafter, mean rates of chronic eGFR decline with dapagliflozin and placebo were −1.9 (−3.0, −0.9) and −4.0 (−4.9, −3.0) mL/min/1.73 m2/year, respectively (difference 2.0, 95% CI 0.6 to 3.5, mL/min/1.73 m2/year).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“With respect to limitations, the DAPA-CKD study was not specifically designed to test our hypothesis in patients with FSGS, and the relatively small sample size of this subgroup limited the precision of estimates of treatment effects on the study endpoints.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
No SGLT2 inhibitor data specific to APOL1 kidney disease
“Of note, much of the data on CKD progression due to APOL1 variants came before the widespread use of sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dual angiotensin and endothelin receptor antagonists, and it is unclear whether such therapies influence disease development or progression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote